ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and Lymphoma

NCT03895944 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

18

Enrollment

OTHER

Sponsor class

Conditions

CD19+ Lymphoma, B-Cell
CD19+ Leukemia, B-Cell

Interventions

BIOLOGICAL: ET190L1-ARTEMIS™ T cells -iv low dose
BIOLOGICAL: ET190L1-ARTEMIS™ T cells -iv middle dose
BIOLOGICAL: ET190L1-ARTEMIS™ T cells - iv high dose

Sponsor

First Affiliated Hospital Xi'an Jiaotong University

Collaborators

[object Object]